EssilorLuxottica announces launch of share buyback program
Charenton-le-Pont, France (17 June 2022 – 7:00 am) – EssilorLuxottica announces the launch of a share buyback program reflecting the Group’s confidence in its value creation and long-term prospects.
With a view to implementing this share buyback program, EssilorLuxottica has granted a mandate to an investment services provider for the purchase of up to 2,500,000 EssilorLuxottica shares, depending on market conditions, over a period starting from today, 17 June 2022, up until 31 August 2022 included.
The shares so acquired are intended to be awarded or transferred to employees and corporate directors of EssilorLuxottica and affiliated companies, especially in the context of profit-sharing plans, bonus and performance share awards, stock option plans, and employee share ownership plans.
EssilorLuxottica launches this share buyback program in accordance to the 14th resolution approved by the Annual General Meeting of 25 May 2022, during which the Company was granted the right to purchase its own shares during the 18 months that followed the Annual General Meeting, for an amount representing up to 10% of its share capital and for a price per share not exceeding Euro 200.
A description of this share buyback program is available as an appendix to this press release as well as here.
APPENDIX
(only available in French)
EssilorLuxottica
Société anonyme au capital de 79.672.548, 24 euros
Siège social : 147 rue de Paris – 94420 Charenton-le-Pont
712 049 618 RCS Créteil
(la Société)
Descriptif du programme de rachat d’actions
Charenton-le-Pont, France (16 juin 2022) – Conformément aux dispositions de l’article 5 du règlement 596/2014, de l’article 2 du règlement délégué 2016/1052 et de l’article 241-2 du règlement général de l’AMF, le présent descriptif a pour objectif de décrire les finalités et les modalités du programme de rachat de ses propres actions par la société. Ce programme a été approuvé par l’Assemblée générale mixte du 25 mai 2022 et est mis en œuvre sur la base d’une décision du Conseil d’administration. Ce programme présente les caractéristiques suivantes :
La présente publication est disponible sur le site de la Société ici.
Attachment
* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen's Devices were showcased at…
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…
Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…
TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…